Friedrich Carl von Rundstedt1, Seth P Lerner1, Guilherme Godoy1, Gilad Amiel1, Thomas M Wheeler1, Luan D Truong1, Steven S Shen2. 1. Scott Department of Urology, Department of Pathology, Baylor College of Medicine, Houston, Texas; Department of Pathology and Genomic Medicine, Houston Methodist Hospital (LDT, SSS), Houston, Texas. 2. Scott Department of Urology, Department of Pathology, Baylor College of Medicine, Houston, Texas; Department of Pathology and Genomic Medicine, Houston Methodist Hospital (LDT, SSS), Houston, Texas. Electronic address: stevenshen@houstonmethodist.org.
Abstract
PURPOSE: We determined the likelihood that transurethral resection biopsy of the prostatic urethra adjacent to the verumontanum would detect prostatic involvement of urothelial carcinoma in patients with bladder carcinoma. MATERIALS AND METHODS: We compared precystectomy transurethral resection biopsy specimens of the prostatic urethra with those of the matched radical cystoprostatectomy in 272 patients with urothelial carcinoma of the bladder. All prostates were evaluated by whole mount step sections. RESULTS: Prostatic involvement by urothelial carcinoma was detected by transurethral resection biopsy or radical cystoprostatectomy in 101 patients (37.1%). Transurethral resection biopsy detected urothelial carcinoma in 72 cases with 71.3% sensitivity and 100% specificity. The overall accuracy of transurethral resection biopsy to detect urothelial carcinoma of the prostate was 89% (positive and negative predictive values 100% and 86%, respectively). Invasive prostatic urothelial carcinoma arising from the prostatic urethra was detected by transurethral resection biopsy in 21 of 26 patients (81%) while prostatic carcinoma in situ was detected in 39 of 52 (75%). Transurethral resection biopsy detected prostatic invasive urothelial carcinoma resulting from transmural invasion of a bladder tumor in 4 of 15 patients. CONCLUSIONS: Prostatic involvement by urothelial carcinoma of the bladder was found in 37.1% of patients. Transurethral resection biopsy missed most tumors resulting from transmural invasion of the bladder primary lesion. Carcinoma in situ and invasive urothelial carcinoma arising from the prostatic urethra were detected in most cases. Transurethral resection biopsy of the prostatic urethra can complement staging and support clinical decision making with respect to neoadjuvant chemotherapy and planning for an orthotopic neobladder.
PURPOSE: We determined the likelihood that transurethral resection biopsy of the prostatic urethra adjacent to the verumontanum would detect prostatic involvement of urothelial carcinoma in patients with bladder carcinoma. MATERIALS AND METHODS: We compared precystectomy transurethral resection biopsy specimens of the prostatic urethra with those of the matched radical cystoprostatectomy in 272 patients with urothelial carcinoma of the bladder. All prostates were evaluated by whole mount step sections. RESULTS: Prostatic involvement by urothelial carcinoma was detected by transurethral resection biopsy or radical cystoprostatectomy in 101 patients (37.1%). Transurethral resection biopsy detected urothelial carcinoma in 72 cases with 71.3% sensitivity and 100% specificity. The overall accuracy of transurethral resection biopsy to detect urothelial carcinoma of the prostate was 89% (positive and negative predictive values 100% and 86%, respectively). Invasive prostatic urothelial carcinoma arising from the prostatic urethra was detected by transurethral resection biopsy in 21 of 26 patients (81%) while prostatic carcinoma in situ was detected in 39 of 52 (75%). Transurethral resection biopsy detected prostatic invasive urothelial carcinoma resulting from transmural invasion of a bladder tumor in 4 of 15 patients. CONCLUSIONS: Prostatic involvement by urothelial carcinoma of the bladder was found in 37.1% of patients. Transurethral resection biopsy missed most tumors resulting from transmural invasion of the bladder primary lesion. Carcinoma in situ and invasive urothelial carcinoma arising from the prostatic urethra were detected in most cases. Transurethral resection biopsy of the prostatic urethra can complement staging and support clinical decision making with respect to neoadjuvant chemotherapy and planning for an orthotopic neobladder.
Authors: D Esrig; J A Freeman; D A Elmajian; J P Stein; S C Chen; S Groshen; A Simoneau; E C Skinner; G Lieskovsky; S D Boyd; R J Cote; D G Skinner Journal: J Urol Date: 1996-09 Impact factor: 7.450
Authors: Daniel A Barocas; Sanjay G Patel; Sam S Chang; Peter E Clark; Joseph A Smith; Michael S Cookson Journal: BJU Int Date: 2009-04-15 Impact factor: 5.588
Authors: Monica P Revelo; Michael S Cookson; Sam S Chang; M Frances Shook; Joseph A Smith; Scott B Shappell Journal: J Urol Date: 2004-02 Impact factor: 7.450
Authors: Joseph A Pettus; Hikmat Al-Ahmadie; Daniel A Barocas; Theresa M Koppie; Harry Herr; S Machele Donat; Guido Dalbagni; Victor E Reuter; Semra Olgac; Bernard H Bochner Journal: Eur Urol Date: 2007-07-26 Impact factor: 20.096
Authors: Aaron Brant; Marcus Daniels; Meera R Chappidi; Gregory A Joice; Nikolai A Sopko; Andres Matoso; Trinity J Bivalacqua; Max Kates Journal: World J Urol Date: 2019-03-08 Impact factor: 4.226
Authors: Georgios Gakis; Peter C Black; Bernard H Bochner; Stephen A Boorjian; Arnulf Stenzl; George N Thalmann; Wassim Kassouf Journal: Eur Urol Date: 2016-10-06 Impact factor: 20.096
Authors: Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens Journal: Can Urol Assoc J Date: 2016-02-08 Impact factor: 1.862